Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures

EREN, FULYA; Ceyhan Dirican, Ayten; Baybas, Sevim; Atakli, Hayrunisa Dilek; tekin, betül; Gul, Gunay

doi:10.14744/epilepsi.2020.59244

Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures

Fulya EREN, (Bakırköy Sağlık Bilimleri Üniversitesi, Nöroloji Anabilim Dalı, Prof. Dr. Mazhar Osman Ruh Sağlığı ve Nöroloji Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye)

Ayten Ceyhan DİRİCAN, (Girilmemişş)

Günay GÜL, (Girilmemişş)

Betül TEKİN, (Girilmemişş)

Dilek ATAKLI, (Girilmemişş)

Sevim BAYBAŞ (Girilmemişş)

Epilepsi

3 0

Yıl: 2021 Cilt: 27 Sayı: 1 Sayfa Aralığı: 47 - 51 Metin Dili: İngilizce DOI: 10.14744/epilepsi.2020.59244 İndeks Tarihi: 05-06-2021

Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures

Öz:

Objectives: Lacosamide (LCM) is a new generation amino acid drug that is used in patients with drug-resistant epilepsy, which increases the slow inactivation of voltage-dependent sodium channels. In this study, the short-term results of patients with drug-resistant epilepsy who received add-on LCM therapy were evaluated. Methods: Patients who were at least 16 years old and had focal onset seizures for a minimum period of 1 year were retrospectively assessed. Those who had uncontrolled seizures, despite the use of two appropriate antiepileptic drugs at an effective dose for at least six months, were included in the study. Forty-five eligible patients (11 females, 34 males) underwent further analysis. LCM therapy doses, change in seizure fre-quency, number of seizures before and after LCM therapy, and the effect of LCM add-on therapy on seizures were analyzed. Results: The mean age of the included 45 patients (11 females, 34 males) was 31.42 (16–56) years. Twenty-six of 45 (57.8%) patients under add-on therapy showed a decrease of 50% or more. It was observed that the seizure frequency decreased to a median of 2 (IQR: 0.5–5), which was statistically significant (p<0.001). The dose was not correlated with the seizure decrease ratio (p=0.216). The decrease in seizure frequency was similar in patients with LCM add-on treatment as the second or third drug, when compared with patients using LCM as the fourth or fifth drug (p=0.231).Conclusion: It was observed that LCM add-on therapy significantly decreased seizure frequency, similar to the current literature. On the con-trary, the dose effect or earlier add-on therapy did not show a significant effect on seizure frequency. LCM should be considered as a successful treatment option in patients with drug-resistant focal onset seizures.

Anahtar Kelime:

Fokal Başlangıçlı Nöbetleri Olan Dirençli Epilepsi HastalarındaLakozamid Ekleme Tedavisinin Kısa Dönem Sonuçları

Öz:

Amaç: Lakozamid, fokal başlangıçlı nöbetleri olan dirençli epilepsi hastalarında kullanılan voltaj bağımlı sodyum kanallarının yavaş inakti-vasyonunu arttıran yeni nesil bir aminoasittir. Bu çalışmada, dirençli epilepsi hastalarında lakozamid ekleme tedavisinin kısa süreli takipteki sonuçlarının değerlendirilmesi amaçlanmıştır.Gereç ve Yöntem:Hastanemiz epilepsi polikliniklerine başvuran en az bir yıldır fokal başlangıçlı nöbetleri olan 16 yaş üstü hastaların bilgileri retrospektif olarak taranmıştır. Bu hastalar arasından en az altı aydır uygun iki antiepileptik ilacı efektif dozda kullanmasına rağmen nöbetleri kontrol altına alınamayan ve tedavisinde lakozamid bulunan hastalar çalışmaya dahil edilmiştir. Bu kriterlere uyan 48 hastadan bir ay ve üzeri lakozamid kullanan 45’i analiz edilmiştir. Hastaların tedavi dozu ve nöbet sıklığındaki yüzde azalması, öncesi ve sonrasındaki nöbet sıklıkları, ekleme tedavisinin sırasının nöbet sıklığına etkisi analiz edilmiştir.Bulgular: Çalışmaya dahil edilen 45 (11’i kadın, 34’ü erkek) hastanın yaş ortalaması 31.42 (16-56 yıl) yıl idi. Tedaviye devam eden 45 hastadan 26’sının (%57.8) aylık nöbet sıklığında %50 ve üzerinde azalma tespit edilmiştir. Tedavi sonrası aylık nöbet sıklıklarının medyan 2 (IQR=0.5-5) düzeyine gerilediği izlenmiş ve bu değer istatistiksel olarak anlamlı bulunmuştur (p<0.001). Hastaların kullandıkları doz ile azalma yüzdesi arasında istatistiksel olarak anlamlı fark izlenmemiştir (p=0.216). İkinci ve üçüncü antiepileptik ilaç olarak eklenen hastalar ile dördüncü ve beşinci antiepileptik ilaç olarak eklenen hastalar karşılaştırıldığında nöbet sıklığındaki azalma ile aralarında istatistiksel anlamlı ilişki tespit edilmemiştir (p=0.231).Sonuç:Çalışmamızda lakozamid ekleme tedavisinin nöbet sıklığını literatür ile uyumlu olarak azalttığı gözlenmiştir. Doz ve erken eklemenin nöbet sıklığı üzerine etkisi olmadığı tespit edilmiştir. Lakozamid, fokal başlangıçlı dirençli epilepsi hastalarında ekleme tedavisinde iyi tolere edilebilen bir seçenek olarak akılda tutulmalıdır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hu Q, Zhang F, Teng W, Hao F, Zhang J, Yin M, et al. Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis. J Neurol 2018;265(1):1–11.
2. Shneker BF, Fountain NB. Epilepsy. Dis Mon 2003;49(7):426–78.
3. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(8 Suppl 5):S2–8.
4. Picot MC, Baldy-Moulinier M, Daurès JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 2008;49(7):1230–8.
5. Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ 2014;348:g254.
6. Baker MD, Abou-Khalil BW, Arain A, Tummala P, Azar NJ, Haas KF, et al. Lacosamide efficacy and tolerability in clinical practice - Post marketing analysis from a single dedicated epilepsy center. Clin Neurol Neurosurg 2018;171:179–83.
7. Hoy SM. Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy. CNS Drugs 2018;32(5):473–84.
8. Paquette V, Culley C, Greanya ED, Ensom MH. Lacosamide as adjunctive therapy in refractory epilepsy in adults: a systematic review. Seizure 2015;25:1–17.
9. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443- 53.
10. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48(7):1308–17.
11. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 2001;47(1-2):17–25.
12. Rosenow F, Kelemen A, Ben-Menachem E, McShea C, Isojarvi J, Doty P; SP774 study investigators. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures. Acta Neurol Scand 2016;133(2):136–44.
13. Neal A, D’Souza W, Hepworth G, Lawn N, Cook M, Nikpour A. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs. Epilepsy Behav 2018;80:25–32.
14. Schultz L, Mahmoud SH. Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy? Eur J Drug Metab Pharmacokinet 2020;45(3):315–49.
15. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011;20(1):20–3.
16. Villanueva V, Garcés M, López-Gomáriz E, Serratosa JM, González-Giráldez B, Parra J, et al. Early add-on lacosamide in a real-life setting: results of the REALLY study. Clin Drug Investig 2015;35(2):121–31.
17. Villanueva V, Giráldez BG, Toledo M, De Haan GJ, Cumbo E, Gambardella A, et al. Lacosamide monotherapy in clinical practice: A retrospective chart review. Acta Neurol Scand 2018;138(3):186–94.
18. Wechsler RT, Yates SL, Messenheimer J, Leroy R, Beller C, Doty P. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension. Epilepsy Res 2017;130:13–20

APA	EREN F, Ceyhan Dirican A, Gul G, tekin b, Atakli H, Baybas S (2021). Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. , 47 - 51. 10.14744/epilepsi.2020.59244
Chicago	EREN FULYA,Ceyhan Dirican Ayten,Gul Gunay,tekin betül,Atakli Hayrunisa Dilek,Baybas Sevim Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. (2021): 47 - 51. 10.14744/epilepsi.2020.59244
MLA	EREN FULYA,Ceyhan Dirican Ayten,Gul Gunay,tekin betül,Atakli Hayrunisa Dilek,Baybas Sevim Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. , 2021, ss.47 - 51. 10.14744/epilepsi.2020.59244
AMA	EREN F,Ceyhan Dirican A,Gul G,tekin b,Atakli H,Baybas S Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. . 2021; 47 - 51. 10.14744/epilepsi.2020.59244
Vancouver	EREN F,Ceyhan Dirican A,Gul G,tekin b,Atakli H,Baybas S Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. . 2021; 47 - 51. 10.14744/epilepsi.2020.59244
IEEE	EREN F,Ceyhan Dirican A,Gul G,tekin b,Atakli H,Baybas S "Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures." , ss.47 - 51, 2021. 10.14744/epilepsi.2020.59244
ISNAD	EREN, FULYA vd. "Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures". (2021), 47-51. https://doi.org/10.14744/epilepsi.2020.59244

APA	EREN F, Ceyhan Dirican A, Gul G, tekin b, Atakli H, Baybas S (2021). Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. Epilepsi, 27(1), 47 - 51. 10.14744/epilepsi.2020.59244
Chicago	EREN FULYA,Ceyhan Dirican Ayten,Gul Gunay,tekin betül,Atakli Hayrunisa Dilek,Baybas Sevim Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. Epilepsi 27, no.1 (2021): 47 - 51. 10.14744/epilepsi.2020.59244
MLA	EREN FULYA,Ceyhan Dirican Ayten,Gul Gunay,tekin betül,Atakli Hayrunisa Dilek,Baybas Sevim Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. Epilepsi, vol.27, no.1, 2021, ss.47 - 51. 10.14744/epilepsi.2020.59244
AMA	EREN F,Ceyhan Dirican A,Gul G,tekin b,Atakli H,Baybas S Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. Epilepsi. 2021; 27(1): 47 - 51. 10.14744/epilepsi.2020.59244
Vancouver	EREN F,Ceyhan Dirican A,Gul G,tekin b,Atakli H,Baybas S Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures. Epilepsi. 2021; 27(1): 47 - 51. 10.14744/epilepsi.2020.59244
IEEE	EREN F,Ceyhan Dirican A,Gul G,tekin b,Atakli H,Baybas S "Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures." Epilepsi, 27, ss.47 - 51, 2021. 10.14744/epilepsi.2020.59244
ISNAD	EREN, FULYA vd. "Short-term Results of The Add-on Lacosamide Therapyin Patients with Drug-resistant Focal Onset Seizures". Epilepsi 27/1 (2021), 47-51. https://doi.org/10.14744/epilepsi.2020.59244